Barliman I

Yale University

July 25, 1988

Department of Biology Osborn Memorial Laboratories P.O. Box 6666 New Haven, Connecticut 06511-7444

Campus address:
Osborn Memorial Laboratories
165 Prospect Street
Telephone:
203 432-3850

THE NUCKEFULL R UNIVERSITY

JUL 2 / 1988

Dr. Joshua Lederberg, President Rockefeller University 1230 York Avenue New York, New York 10021

Dear Josh:

Persons working on \underline{E} . $\underline{\operatorname{coli}}$ genetics and molecular biology have been very good about sharing their strains, plasmids, and DNA fragments. We have had very few refusals when we requested strains for distribution from the Stock Center. At this moment, I can think of only one person who would not send out his unique mutant for, I think, around 5 years. By then, other labs had isolated mutants at the same locus so he was largely ignored.

Some labs don't want to distribute a mutant as soon as it is published because they want to give a graduate student a chance to complete his work - or a post-doc. A student can spend a year or two isolating a new type of mutation, with patience, skill and ingenuity, in order to do a biochemical or molecular study. There are big labs which would love to take the mutant and quickly do the experiment toward which he has been working. (Labs that could not have isolated the mutant in the first place.) I am entirely in favor of protecting the student (or post-doc) in cases like this, and I think that almost all people in the field share this attitude.

I am trying to revise the linkage map and so am ploughing through the literature. I see in paper after paper thanks to other labs who sent mutants, plasmids, DNA fragments and unpublished information to the authors of the papers. I don't think that there is a problem in \underline{E} . $\underline{\operatorname{coli}}$ genetics. I hear that the situation in the "biomedical sciences" is another matter, but I don't have any idea as to what can be done about that. It may be related to other problems of the field of medicine which will need to be solved first.

Regarding the $\underline{mt1}$ mutants, I'm not sure that I understand exactly what it is you want to know.

You isolated two Mtl (mannitol non-utilizing) mutants very early:

 $\underline{\mathsf{mtl}}-1$ is in strain W945 and $\mathsf{mtl}-2$ in strain W595.

 $\frac{\text{mt1-2}}{2}$ is now thought to be a mutation in the $\frac{\text{mt1A}}{2}$ locus (Lengeler and Lin 1972 J. Bacteriol. 111:566).

18/3/18 203 × 15/14303 This mutation is polar so the strain carrying this mutation lacks both the mannitol specific Enzyme II of the phosphotransferase system (PTS), coded by the mtlA gene and the mannitol-l-phosphate dehydrogenase, coded for by the mtlA gene.

 $\underline{\text{mtl-1}}$ is also probably a mutation in $\underline{\text{mtlA}}$. Strains carrying this mutation lack the $\underline{\text{mtlA}}$ product but have "unusual" levels of the $\underline{\text{mtlD}}$ product and do not appear to be regulated normally. For this reason we still just list this mutation as $\underline{\text{mtl-1}}$ rather than as $\underline{\text{mtlAl}}$.

I hope that this answers your questions.

Sincerely,

Barbara J. Bachmann

Barbara

Curator, E. coli Genetic Stock Center